Studies in animals suggest that the bispiperazinedione ICRF-187 can prevent the development of dose-related doxorubicin-induced cardiac toxicity. In a randomized trial in 92 women with advanced breast cancer, we compared treatment with fluorouracil, doxorubicin, and cyclophosphamide (FDC), given every 21 days, with the same regimen preceded by administration of ICRF-187 (FDC + ICRF-187). Patients were withdrawn from the study when cardiac toxicity developed or the cancer progressed. The mean cumulative dose of doxorubicin tolerated by patients withdrawn from study was 397.2 mg per square meter of body-surface area in the FDC group and 466.3 mg in the FDC + ICRF-187 group (no significant difference). Eleven patients on the FDC + ICRF-187 arm received cumulative doxorubicin doses above 600 mg per square meter, whereas one receiving FDC was able to remain in the study beyond this dose. Antitumor response rates were similar (FDC vs. FDC + ICRF-187, 3 vs. 4 complete responses; 17 vs. 17 partial responses; and 9.3 vs. 10.3 months to disease progression). Although myelosuppression was slightly greater in the FDC + ICRF-187 group, the incidence of fever, infections, alopecia, nausea and vomiting, or death due to toxicity did not differ between the groups. Cardiac toxicity was evaluated by clinical examination, determination of the left ventricular ejection fraction by multigated nuclear scans, and endomyocardial biopsy. In comparisons of the FDC group with the FDC + ICRF-187 group, clinical congestive heart failure was observed in 11 as compared with 2 patients; the mean decrease in the left ventricular ejection fraction was 7 vs. 1 percent when the cumulative dose of doxorubicin was 250 to 399 mg per square meter (P = 0.02), 16 vs. 1 percent at 400 to 499 mg (P = 0.001), and 16 vs. 3 percent at 500 to 599 mg (P = 0.003); and the Billingham biopsy score was 2 or more in 5 of 13 patients undergoing biopsy vs. none of 13 (P = 0.03). We conclude that ICRF-187 offers significant protection against cardiac toxicity caused by doxorubicin, without affecting the antitumor effect of doxorubicin or the incidence of noncardiac toxic reactions.
Source Information
Rita & Stanley Kaplan Cancer Center, New York.
This article has been cited by other articles:
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., Sawyer, D. B.
(2008). Anthracycline Cardiotoxicity: From Bench to Bedside. JCO
26: 3777-3784
[Abstract][Full Text]
Steinherz, L.
(2008). Early Breast Cancer Therapy and Cardiovascular Injury. J Am Coll Cardiol
51: 1235-1235
[Full Text]
Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Larsen, E. C., Moghrabi, A., Samson, Y., Schorin, M. A., Cohen, H. J., Lipshultz, S. E., Sallan, S. E., Silverman, L. B.
(2008). Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane. JCO
26: 1106-1111
[Abstract][Full Text]
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., Schwartz, C. L.
(2007). Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease. JCO
25: 493-500
[Abstract][Full Text]
Marty, M., Espie, M., Llombart, A., Monnier, A., Rapoport, B. L., Stahalova, V., On behalf of the Dexrazoxane Study Group,
(2006). Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol
17: 614-622
[Abstract][Full Text]
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., Perry, M. C.
(2005). Cardiotoxicity of Cancer Therapy. JCO
23: 7685-7696
[Abstract][Full Text]
Hofland, K. F., Thougaard, A. V., Sehested, M., Jensen, P. B.
(2005). Dexrazoxane Protects against Myelosuppression from the DNA Cleavage-Enhancing Drugs Etoposide and Daunorubicin but not Doxorubicin. Clin. Cancer Res.
11: 3915-3924
[Abstract][Full Text]
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., Gelber, R. D., Sallan, S. E.
(2004). The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia. NEJM
351: 145-153
[Abstract][Full Text]
L'Ecuyer, T., Allebban, Z., Thomas, R., Vander Heide, R.
(2004). Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol.
286: H2057-H2064
[Abstract][Full Text]
Kotamraju, S., Chitambar, C. R., Kalivendi, S. V., Joseph, J., Kalyanaraman, B.
(2002). Transferrin Receptor-dependent Iron Uptake Is Responsible for Doxorubicin-mediated Apoptosis in Endothelial Cells. ROLE OF OXIDANT-INDUCED IRON SIGNALING IN APOPTOSIS. J. Biol. Chem.
277: 17179-17187
[Abstract][Full Text]
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., Cipolla, C. M.
(2002). Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol
13: 710-715
[Abstract][Full Text]
Tetef, M. L., Synold, T. W., Chow, W., Leong, L., Margolin, K., Morgan, R., Raschko, J., Shibata, S., Somlo, G., Yen, Y., Groshen, S., Johnson, K., Lenz, H.-J., Gandara, D., Doroshow, J. H.
(2001). Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies. Clin. Cancer Res.
7: 1569-1576
[Abstract][Full Text]
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., Fiorentini, C.
(2000). Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol
36: 517-522
[Abstract][Full Text]
van Acker, F. A. A., van Acker, S. A. B. E., Kramer, K., Haenen, G. R. M. M., Bast, A., van der Vijgh, W. J. F.
(2000). 7-Monohydroxyethylrutoside Protects against Chronic Doxorubicin-induced Cardiotoxicity When Administered Only Once Per Week. Clin. Cancer Res.
6: 1337-1341
[Abstract][Full Text]
Yoshida, M., Maehara, Y., Sugimachi, K.
(1999). MST-16, a Novel Bis-dioxopiperazine Anticancer Agent, Ameliorates Doxorubicin-induced Acute Toxicity While Maintaining Antitumor Efficacy. Clin. Cancer Res.
5: 4295-4300
[Abstract][Full Text]
Hensley, M. L., Schuchter, L. M., Lindley, C., Meropol, N. J., Cohen, G. I., Broder, G., Gradishar, W. J., Green, D. M., Langdon, R. J. Jr, Mitchell, R. B., Negrin, R., Szatrowski, T. P., Thigpen, J. T., Von Hoff, D., Wasserman, T. H., Winer, E. P., Pfister, D. G.
(1999). American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. JCO
17: 3333-3355
[Abstract][Full Text]
Feenstra, J., Grobbee, D. E., Remme, W. J., Stricker, B. H. C.
(1999). Drug-induced heart failure. J Am Coll Cardiol
33: 1152-1162
[Abstract][Full Text]
Klein, P., Muggia, F. M.
(1999). Cytoprotection: Shelter from the Storm. The Oncologist
4: 112-121
[Full Text]
Sawyer, D. B., Fukazawa, R., Arstall, M. A., Kelly, R. A.
(1999). Daunorubicin-Induced Apoptosis in Rat Cardiac Myocytes Is Inhibited by Dexrazoxane. Circ. Res.
84: 257-265
[Abstract][Full Text]
MINOTTI, G., CAIRO, G., MONTI, E.
(1999). Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB J.
13: 199-212
[Abstract][Full Text]
O'Marcaigh, A. S., Betcher, D. L.
(1997). Dexrazoxane (ICRF-187): A Cardioprotective Agent During Anthracycline Chemotherapy. Journal of Pediatric Oncology Nursing
14: 96-98
Dunn, J.
(1994). Doxorubicin-Induced Cardiomyopathy. Journal of Pediatric Oncology Nursing
11: 152-160
[Abstract]
Davis, L. E.
(1991). Long-Term Complications of Antineoplastic Agents. Journal of Pharmacy Practice
4: 131-150
Previous
